The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 12, 2023

Filed:

Jan. 12, 2022
Applicant:

Impel Pharmaceuticals Inc., Seattle, WA (US);

Inventors:

John D. Hoekman, Seattle, WA (US);

Kelsey H. Satterly, Seattle, WA (US);

Inna Dashevsky, Seattle, WA (US);

Aditya R. Das, Foster City, CA (US);

Assignee:

Impel Pharmaceuticals Inc., Seattle, WA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 31/5513 (2006.01); A61M 15/00 (2006.01); A61K 9/16 (2006.01); A61P 25/18 (2006.01); A61K 31/00 (2006.01);
U.S. Cl.
CPC ...
A61K 9/0043 (2013.01); A61K 9/16 (2013.01); A61K 9/1617 (2013.01); A61K 9/1623 (2013.01); A61K 9/1652 (2013.01); A61K 31/00 (2013.01); A61K 31/5513 (2013.01); A61M 15/003 (2014.02); A61P 25/18 (2018.01);
Abstract

Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (C) of at least 30 ng/mL, with (b) a mean time to C(T) of olanzapine of less than 0.5 hours. Dry pharmaceutical compositions and devices suitable for intranasal delivery of olanzapine are provided.


Find Patent Forward Citations

Loading…